A5101987854- Cancer Genomics and Diagnostics
- Single-cell and spatial transcriptomics
- CRISPR and Genetic Engineering
- Genetic factors in colorectal cancer
- Pediatric health and respiratory diseases
- Respiratory viral infections research
- Inhalation and Respiratory Drug Delivery
- Cancer Cells and Metastasis
- Lymphoma Diagnosis and Treatment
- Parasitic Infections and Diagnostics
- Viral-associated cancers and disorders
- Spectroscopy and Quantum Chemical Studies
- Protein Structure and Dynamics
- CAR-T cell therapy research
- Protist diversity and phylogeny
- Enzyme Structure and Function
- Monoclonal and Polyclonal Antibodies Research
- Molecular Biology Techniques and Applications
- Ultrasound Imaging and Elastography
- interferon and immune responses
- Environmental DNA in Biodiversity Studies
- Echinoderm biology and ecology
- Advanced biosensing and bioanalysis techniques
- Breast Cancer Treatment Studies
- Toxoplasma gondii Research Studies
Broad Institute
2023-2025
Georgia Institute of Technology
2024
Massachusetts Institute of Technology
2023
Boston University
2021
AstraZeneca (United States)
2020
La Roche College
2012
Liquid biopsies enable early detection and monitoring of diseases such as cancer, but their sensitivity remains limited by the scarcity analytes cell-free DNA (cfDNA) in blood. Improvements to have primarily relied on enhancing sequencing technology ex vivo. We sought transiently augment level circulating tumor (ctDNA) a blood draw attenuating its clearance report two intravenous priming agents given 1 2 hours before recover more ctDNA. Our consist nanoparticles that act cells responsible...
Abstract Detecting mutations from single DNA molecules is crucial in many fields but challenging. Next-generation sequencing (NGS) affords tremendous throughput cannot directly sequence double-stranded (‘single duplexes’) to discern the true on both strands. Here we present Concatenating Original Duplex for Error Correction (CODEC), which confers duplex resolution NGS. CODEC 1,000-fold higher accuracy than NGS, using up 100-fold fewer reads sequencing. revealed mutation frequencies of 2.72 ×...
Minimally invasive molecular profiling using cell-free DNA (cfDNA) is increasingly important to the management of cancer patients; however, low sensitivity remains a major limitation, particularly for brain tumor patients. Transiently attenuating cfDNA clearance from body-thereby, allowing more be sampled-has been proposed improve performance liquid biopsy diagnostics. However, there paucity clinical data on effect higher recovery. Here, we investigated impact collecting greater quantities...
Polyinosinic:polycytidylic acid (poly I:C) is a synthetic analogue of double-stranded (ds)RNA, molecular pattern associated with viral infections, that used to exacerbate inflammation in lung injury models. Despite its frequent use, there are no detailed studies the responses elicited by single topical administration poly I:C lungs mice. Our data provides first demonstration airways induced correlate those observed chronic obstructive pulmonary disease (COPD) patients. These expression also...
ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTProtein Hydration Investigations with High-Frequency Dielectric SpectroscopyYan-Zhen Wei, A. C. Kumbharkhane, M. Sadeghi, J. T. Sage, W. D. Tian, P. Champion, S. Sridhar, and McDonaldCite this: Phys. Chem. 1994, 98, 26, 6644–6651Publication Date (Print):June 1, 1994Publication History Published online1 May 2002Published inissue 1 June 1994https://pubs.acs.org/doi/10.1021/j100077a034https://doi.org/10.1021/j100077a034research-articleACS...
Blood-based, or "liquid," biopsies enable minimally invasive diagnostics but have limits on sensitivity due to scarce cell-free DNA (cfDNA). Improvements primarily relied enhancing sequencing technology ex vivo . Here, we sought augment the level of circulating tumor (ctDNA) detected in a blood draw by attenuating clearance cfDNA We report first-in-class intravenous DNA-binding priming agent given 2 hours prior recover more cfDNA. The antibody minimizes nuclease digestion and organ uptake...
To examine circulating tumor DNA (ctDNA) and its association with residual cancer burden (RCB) using an ultrasensitive assay in patients triple-negative breast (TNBC) receiving neoadjuvant chemotherapy (NAT).We identified responders (RCB-0/1) matched non-responders (RCB-2/3) from the phase II TBCRC 030 prospective study of paclitaxel vs. cisplatin TNBC. We collected plasma samples at baseline, three weeks, twelve weeks (end therapy). created personalized ctDNA assays utilizing MAESTRO...
Tracing patient-specific tumor mutations in cell-free DNA (cfDNA) for minimal residual disease (MRD) detection is promising but challenging. Assaying more and cfDNA stands to improve MRD requires highly accurate, efficient sequencing methods proper calibration prevent false with bespoke tests.
We provide a functional characterization of transcription factor NF-κB in protists and information about the evolution diversification this biologically important protein. characterized two using phylogenetic, cellular, biochemical techniques. holozoan Capsaspora owczarzaki (Co) has an N-terminal DNA-binding domain C-terminal Ankyrin repeat (ANK) domain, its specificity is more similar to metazoan proteins than Rel proteins. Removal ANK allows Co-NF-κB enter nucleus, bind DNA, activate...
Abstract HER2-targeted therapies are promising treatment options for metastatic breast cancer and have improved the median overall survival. However, brain metastasis (BCBM), observed in up to 50% of HER2-positive patients, remains a clinical challenge. While Chimeric Antigen Receptor (CAR) T cell therapy is therapeutic strategy address unmet need treating BCBM, improving its effectiveness safety critical translation. We hypothesized that spatially temporally controlled activity CAR-T cells...
Abstract Background. Patients (pts) with early triple negative breast cancer (eTNBC) are at increased risk of recurrence and death. Recent studies have focused on escalation therapy, current treatment standard least five drugs – associated toxicities - for eTNBC. Though presence residual disease after neoadjuvant therapy (NAT) as measured by burden (RCB) helps guide addition adjuvant treatment, more effective tools to tailor limited. Persistence circulating tumor DNA (ctDNA) in the setting...
Abstract Liquid biopsies using cell-free DNA (cfDNA) enable non-invasive detection and characterization of disease. Advances in sequencing methods have significantly improved the performance liquid biopsies. Yet, despite these advances, sensitivity remains a fundamental challenge. In oncology, circulating tumor (ctDNA) screening tests only detect 20-40% stage I tumors for minimal residual disease 25-50% after surgery. The major barrier to better is intrinsic low level ctDNA plasma. Physical...
Abstract Liquid biopsy measurements, such as analysis of circulating tumor DNA (ctDNA) shed by cancer cells, have garnered significant attention for their potential to empower the field precision oncology. Given that ctDNA tests could enable minimally invasive monitoring and molecular profiling disease, they are being investigated use in earlier detection via pan-cancer screening tests, tracking evolution inform therapy selection, making treatment decisions during minimal residual disease...
Liquid biopsies are enabling minimally invasive monitoring and molecular profiling of diseases across medicine, but their sensitivity remains limited by the scarcity cell-free DNA (cfDNA) in blood. Here, we report an intravenous priming agent that is given prior to a blood draw increase abundance cfDNA circulation. Our consists nanoparticles act on cells responsible for clearance slow down uptake. In tumor-bearing mice, this increases recovery circulating tumor (ctDNA) up 60-fold improves...
Abstract In this report, we investigate the evolution of transcription factor NF-κB by examining its structure, activity, and regulation in two protists using phylogenetic, cellular, biochemical techniques. Capsaspora owczarzaki ( Co ), find that full-length has an N-terminal DNA-binding domain a C-terminal Ankyrin (ANK) repeat inhibitory domain, activity is more similar to metazoan rather than Rel proteins. As with mammalian proteins, removal ANK repeats required for -NF-κB enter nucleus,...